Amphion Innovations PLC Directorate Change (9662S)
June 29 2018 - 1:01AM
UK Regulatory
TIDMAMP
RNS Number : 9662S
Amphion Innovations PLC
29 June 2018
AMPHION INNOVATIONS PLC
("Amphion" or "the Company")
Appointment of a New Director
London and New York, 29 June 2018 - Amphion Innovations plc
(AIM: AMP), the developer of medical, life science, and technology
businesses, today announces the appointment of Mr Philip Tansey as
Non-executive director to the Company, effective immediately.
Philip Tansey is a qualified chartered accountant (ICAEW) and
holds an honours degree in Biochemistry from Manchester University.
He has over 25 years' experience, primarily in financial services,
having started his career at Salomon Brothers. Until January 2017,
he acted as Chief Financial Officer to the AIM listed company
Panmure Gordon & Co. plc and prior to joining them in May 2011
he worked as a Managing Director for BGC Partners Inc. the NASDAQ
listed inter-dealer broker.
Save as disclosed below, there are no further details required
to be disclosed pursuant to schedule 2(g) of the AIM rules.
Philip Tansey (age 59) is, or has been in the previous five
years, a director or partner, of the following companies:
Current appointments Past appointments
Baby Break and Toddler Durlacher Research Limited
Break Limited
Tansey Associates Limited Life Capital Limited
To Health Limited Panmure General Partner
Limited
Panmure Gordon & Co. Limited
Panmure Gordon (Broking)
Limited
Panmure Gordon (UK) Limited
Panmure Gordon Securities
Limited
Primextend Limited
Rotherfield Nominees Limited
United Energy Limited
United Energy Properties
Limited
Web-Angel Limited
Web-Angel Services Limited
Mr Tansey was a director of Alfresco Leisure Publications Plc
("Alfresco") and its subsidiaries, Premier Guides Limited ("Premier
Guides") and Telfo Limited ("Telfo"), all of which were placed into
administration in 1992. Alfresco Leisure Publications and Premier
Guides were dissolved on 16 November 1999 and Telfo was dissolved
on 7 December 1993. The administrators of Premier Guides showed a
deficiency of GBP0.6 million (excluding amounts owed to Alfresco)
as regards to unsecured creditors. The administrators of Telfo
showed a deficiency to creditors of GBP0.7 million.
Mr Tansey currently holds no beneficial interest in the
Company.
For further information please contact:
Amphion Innovations Tel: +1 (212) 210 6224
Charlie Morgan
Panmure Gordon (UK) Limited (Nominated Tel: +44 (0)20
Adviser and Corporate Broker) 7886 2500
Freddy Crossley / Emma Earl
(Corporate Finance)
Charlie Leigh-Pemberton
(Corporate Broking)
Northland Capital Partners Tel: +44 (0)20
Limited (Joint Corporate Broker) 3861 6625
David Hignell (Corporate
Finance)
John Howes (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933
8780 or
Paul McManus / Anna Dunphy amphion@walbrookpr.com
About Amphion Innovations plc - www.amphionplc.com
Amphion Innovations is a developer of medical, life science and
technology businesses. We use our extensive experience in company
building to invest and build shareholder value in high growth
companies in the US and UK. Amphion has significant shareholding in
7 Partner Companies developing proven technologies targeting
substantial commercial marketplaces. The Amphion model has been
refined to optimise the commercialisation of patents and other
intellectual property within the Partner Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAKMGZVKRNGRZM
(END) Dow Jones Newswires
June 29, 2018 02:01 ET (06:01 GMT)
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2024 to May 2024
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From May 2023 to May 2024